1. Home
  2. LARK vs VTVT Comparison

LARK vs VTVT Comparison

Compare LARK & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Landmark Bancorp Inc.

LARK

Landmark Bancorp Inc.

HOLD

Current Price

$27.25

Market Cap

167.8M

Sector

Finance

ML Signal

HOLD

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$36.70

Market Cap

143.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LARK
VTVT
Founded
1885
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.8M
143.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
LARK
VTVT
Price
$27.25
$36.70
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$55.25
AVG Volume (30 Days)
5.8K
21.1K
Earning Date
01-28-2026
03-19-2026
Dividend Yield
3.07%
N/A
EPS Growth
42.74
N/A
EPS
3.07
N/A
Revenue
$68,286,000.00
$17,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.93
N/A
Revenue Growth
17.39
N/A
52 Week Low
$21.31
$14.00
52 Week High
$29.56
$44.00

Technical Indicators

Market Signals
Indicator
LARK
VTVT
Relative Strength Index (RSI) 53.75 50.19
Support Level $27.10 $31.99
Resistance Level $28.99 $37.98
Average True Range (ATR) 0.76 3.39
MACD 0.02 0.01
Stochastic Oscillator 60.45 45.60

Price Performance

Historical Comparison
LARK
VTVT

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.

Share on Social Networks: